亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

医学 食管静脉曲张 慢性肝病 人口 内科学 肝病 胃肠病学 肝细胞癌 血小板 酒精性肝病 病因学 肝硬化 静脉曲张 门脉高压 环境卫生
作者
Arthur Berger,Federico Ravaioli,Oana Farcau,Davide Festi,Horia Ștefănescu,F. Buisson,Pierre Nahon,Christophe Bureau,Nathalie Ganne‐Carrié,Annalisa Berzigotti,Victor de Lédinghen,Salvatore Petta,Paul Calès,Sylvie Sacher Huvelin,Paul Calès,Dominique Valla,Christophe Bureau,Anne Olivier,Frédéric Oberti,Jérôme Boursier,Jean Paul Galmiche,Jean Pierre Vinel,Clotilde Duburque,Alain Attar,Isabelle Archambeaud,Robert Bénamouzig,M Gaudric,Dominique Luet,Patrice Couzigou,Lucie Planche,Emmanuel Coron,Jean‐Baptiste Hiriart,Faïza Chermak,Maude Charbonnier,Pierre Nahon,Patrick Marcellin,Dominique Guyader,Stanislas Pol,Hélène Fontaine,Dominique Larrey,Victor de Lédinghen,Denis Ouzan,Fabien Zoulim,Dominique Roulot,Albert Tran,Jean‐Pierre Bronowicki,Jean‐Pierre Zarski,Vincent Leroy,Ghassan Riachi,Paul Calès,Jean‐Marie Péron,Laurent Alric,Marc Bourlière,Philippe Maury,Sébastien Dharancy,Jean‐Frédéric Blanc,Armand Abergel,Lawrence Serfaty,Ariane Mallat,Jean‐Didier Grangé,P Attali,Yannick Bacq,Claire Wartelle,Thông Dao,Yves Benhamou,Christophe Pilette,Christine Silvain,Christos Christidis,Dominique Capron,Gérard Thiéfin,Sophie Hillaire,Vincent Di Martino
出处
期刊:Clinical Gastroenterology and Hepatology [Elsevier BV]
卷期号:19 (4): 777-787.e17 被引量:19
标识
DOI:10.1016/j.cgh.2020.06.022
摘要

Background & Aims Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ratio of platelets to liver stiffness. Methods In a retrospective analysis of data from 10 study populations, collected from 2004 through 2018, we randomly assigned data from 2368 patients with chronic liver disease of different etiologies to a derivation population (n = 1579; 15.1% with VNT, 50.2% with viral hepatitis, 28.9% with nonalcoholic fatty liver disease, 20.8% with alcohol-associated liver disease, with model for end-stage liver disease scores of 9.5 ± 3.0, and 93.0% with liver stiffness measurements ≥10 kPa) or a validation population (n = 789). Test results were compared with results from a sequential algorithm (VariScreen). VariScreen incorporated data on platelets or liver stiffness measurements and then the ratio of platelets to liver stiffness measurement, adjusted for etiology, patient sex, and international normalized ratio. Results In the derivation population, endoscopies were spared for 23.9% of patients using the B6C (VNT missed in 2.9%), 24.3% of patients using the ANTICIPATE score (VNT missed in 4.6%), 34.5% of patients using VariScreen (VNT missed in 2.9%), and 41.9% of patients using the EB6C (VNT missed in 10.9%). Differences in spared endoscopy rates were significant (P ≤ .001), except for B6C vs ANTICIPATE and in missed VNT only for EB6C vs the others (P ≤ .009). VariScreen was the only safe test regardless of sex or etiology (missed VNT ≤5%). Moreover, VariScreen secured screening without missed VNT in patients with model for end-stage liver disease scores higher than 10. This overall strategy performed better than a selective strategy restricted to patients with compensated liver disease. Test performance and safety did not differ significantly among populations. Conclusions In a retrospective study of data from 2368 patients with chronic liver disease, we found that the B6C are safe whereas the EB6C are unsafe, based on missed VNT. The VariScreen algorithm performed well in patients with chronic liver disease of any etiology or severity. It is the only test that safely rules out VNT and can be used in clinical practice. Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ratio of platelets to liver stiffness. In a retrospective analysis of data from 10 study populations, collected from 2004 through 2018, we randomly assigned data from 2368 patients with chronic liver disease of different etiologies to a derivation population (n = 1579; 15.1% with VNT, 50.2% with viral hepatitis, 28.9% with nonalcoholic fatty liver disease, 20.8% with alcohol-associated liver disease, with model for end-stage liver disease scores of 9.5 ± 3.0, and 93.0% with liver stiffness measurements ≥10 kPa) or a validation population (n = 789). Test results were compared with results from a sequential algorithm (VariScreen). VariScreen incorporated data on platelets or liver stiffness measurements and then the ratio of platelets to liver stiffness measurement, adjusted for etiology, patient sex, and international normalized ratio. In the derivation population, endoscopies were spared for 23.9% of patients using the B6C (VNT missed in 2.9%), 24.3% of patients using the ANTICIPATE score (VNT missed in 4.6%), 34.5% of patients using VariScreen (VNT missed in 2.9%), and 41.9% of patients using the EB6C (VNT missed in 10.9%). Differences in spared endoscopy rates were significant (P ≤ .001), except for B6C vs ANTICIPATE and in missed VNT only for EB6C vs the others (P ≤ .009). VariScreen was the only safe test regardless of sex or etiology (missed VNT ≤5%). Moreover, VariScreen secured screening without missed VNT in patients with model for end-stage liver disease scores higher than 10. This overall strategy performed better than a selective strategy restricted to patients with compensated liver disease. Test performance and safety did not differ significantly among populations. In a retrospective study of data from 2368 patients with chronic liver disease, we found that the B6C are safe whereas the EB6C are unsafe, based on missed VNT. The VariScreen algorithm performed well in patients with chronic liver disease of any etiology or severity. It is the only test that safely rules out VNT and can be used in clinical practice.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
仁爱的如天完成签到,获得积分10
12秒前
灵巧的朝雪完成签到 ,获得积分10
13秒前
动人的冷霜完成签到,获得积分10
28秒前
Lucas的应助被111采纳,获得10
35秒前
兴奋舞蹈完成签到,获得积分20
43秒前
心随以动完成签到 ,获得积分10
52秒前
修辛完成签到 ,获得积分10
1分钟前
1分钟前
Lucas的应助被科研通管家采纳,获得30
1分钟前
agathahqs的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
agathahqs的应助被科研通管家采纳,获得10
1分钟前
agathahqs的应助被科研通管家采纳,获得10
1分钟前
1分钟前
追寻醉易完成签到,获得积分10
1分钟前
犹豫静白完成签到,获得积分10
1分钟前
舒心鞋垫完成签到,获得积分10
1分钟前
2分钟前
Xuezhuoxin完成签到,获得积分10
2分钟前
威武青寒完成签到,获得积分10
2分钟前
2分钟前
清爽的千易完成签到,获得积分10
2分钟前
woodfire完成签到,获得积分10
2分钟前
毛毛发布了新的文献求助10
2分钟前
2分钟前
3分钟前
3分钟前
AAS完成签到,获得积分10
3分钟前
温暖的胜完成签到,获得积分10
3分钟前
情怀的应助被毛毛采纳,获得10
3分钟前
3分钟前
3分钟前
3分钟前
龚文亮完成签到,获得积分10
3分钟前
激昂的莞完成签到,获得积分10
3分钟前
3分钟前
高高的城发布了新的文献求助10
3分钟前
失眠的白云完成签到,获得积分10
3分钟前
drirshad完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173133
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780452
捐赠科研通 7767182
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555678
邀请新用户注册赠送积分活动 2476675